Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs

Original Research

Accepted on 19 Aug 2025

Oleanolic acid alleviates ovarian cancer by regulating the miR-122/PDK4 axis to induce autophagy and inhibit glycolysis in vivo and in vitro

in Pharmacology of Anti-Cancer Drugs

Zhen Zeng
Qing Lin
Jing Yu
Min Lin
Ningwei Zhao

Frontiers in Oncology

doi 10.3389/fonc.2025.1670758

248 views

Original Research

Published on 18 Aug 2025

Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database

in Pharmacology of Anti-Cancer Drugs

Yu Lin
Xinlei Zheng
Li Lin
Maohua Chen

Frontiers in Oncology

doi 10.3389/fonc.2025.1594585

472 views

Original Research

Accepted on 12 Aug 2025

Cost-effectiveness analysis of the combination of low-dose nivolumab with triple metronomic chemotherapy for advanced head and neck squamous cell carcinoma in China

in Pharmacology of Anti-Cancer Drugs

Yingdan Cao
Fenghao Shi
Yuantong Li
Xiaoxia Wei
Hongbin Yi
Sheng Han
Yu Fang

Frontiers in Oncology

doi 10.3389/fonc.2025.1542792

143 views

Original Research

Accepted on 12 Aug 2025

Osthole Suppresses Prostate Cancer Progression by Modulating PRLR and the JAK2/STAT3 Signaling Axis

in Pharmacology of Anti-Cancer Drugs

Linjun Yan
Yuanqiao He
Qi Cui
Xiaohong Wang
Feng Lv
Keyue Cao
Yuanjian Shao

Frontiers in Oncology

doi 10.3389/fonc.2025.1630181

Review

Published on 11 Aug 2025

Chemotherapeutic nanoparticles for glioblastoma

in Pharmacology of Anti-Cancer Drugs

Samantha Messina
Candida Zuchegna
Mara Bruzzi

Frontiers in Oncology

doi 10.3389/fonc.2025.1641752

475 views

Review

Accepted on 07 Aug 2025

Crucial Roles of CircRNA-Mediated Autophagy in Digestive Cancer

in Pharmacology of Anti-Cancer Drugs

Shenggan Shi
Ailing Wei
Yong Yang
Juan Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1615306

123 views

Case Report

Published on 07 Aug 2025

Acute thrombocytopenia and fibrinogen reduction occurring after nintedanib treatment for immune checkpoint inhibitor-related pneumonia: a case report

in Pharmacology of Anti-Cancer Drugs

Jian Zheng
Nan Zhou
Dexiang Pang

Frontiers in Oncology

doi 10.3389/fonc.2025.1561440

623 views

Original Research

Published on 04 Aug 2025

Integrating network pharmacology and transcriptomics to identify solasonine’s anti-osteosarcoma targets and experimental validation

in Pharmacology of Anti-Cancer Drugs

Daihao Wei
Minyu Li
Dawei Chu
Jiandang Shi

Frontiers in Oncology

doi 10.3389/fonc.2025.1614058

689 views

Original Research

Accepted on 31 Jul 2025

Effects of parthenolide on amino acid metabolism and oxidative stress in lung adenocarcinoma based on quantitative proteomic analysis, targeted amino acid metabolomics, network pharmacology, and experimental validation

in Pharmacology of Anti-Cancer Drugs

Jiye Liu
Yu Liu
Jiachun Li
Shuang Shen

Frontiers in Oncology

doi 10.3389/fonc.2025.1642866

141 views

Review

Published on 30 Jul 2025

Synergistic strategies in photodynamic combination therapy for cancer: mechanisms, nanotechnology, and clinical translation

in Pharmacology of Anti-Cancer Drugs

Daohong Kan
Rong Ding
Huchuan Yang
Yuming Jia
Kaijian Lei
Zhongming Wang
Wei Zhang
Chaokun Yang
Zongjunlin Liu
Fang Xie

Frontiers in Oncology

doi 10.3389/fonc.2025.1607259

754 views

Original Research

Published on 30 Jul 2025

PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib

in Pharmacology of Anti-Cancer Drugs

Yingfang Feng
Yuan Gao
Shaochuan Liu
Tingting Qin
Yan Zhang
Jing Wang
Kai Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1544278

689 views

Original Research

Accepted on 29 Jul 2025

Negative Outcomes Associated with Tyrosine Kinase Inhibitors During Management of Gastrointestinal Stromal Tumors: Examination of Data from the FDA Adverse Event Reporting System

in Pharmacology of Anti-Cancer Drugs

Yuxuan Ma
Ahui Fan
Yuhao Wang
Xu Shenhui
Xin Liu
Jianjun Yang

Frontiers in Oncology

doi 10.3389/fonc.2025.1608451

168 views

Editorial

Published on 17 Jul 2025

Editorial: Safety consideration in the development of anti-tumor monoclonal antibodies during drug development

in Pharmacology of Anti-Cancer Drugs

Tao Wang
Shaad Essa Abedin
Jan Willem van der Laan

Frontiers in Oncology

doi 10.3389/fonc.2025.1640377

710 views

Systematic Review

Published on 17 Jul 2025

A bibliometric and visual analysis of Jak1 to explore trends and frontiers

in Pharmacology of Anti-Cancer Drugs

Cong Yu
Jiamin Cao
Xiaodong Xie
Wenguang Chen
Ensi Hong

Frontiers in Oncology

doi 10.3389/fonc.2025.1537508

994 views

Original Research

Published on 17 Jul 2025

Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER

in Pharmacology of Anti-Cancer Drugs

Xiaomeng Di
Xiaohong Shi
Feng Gai
Jiawei Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1621045

1,516 views
1 citation

Original Research

Published on 16 Jul 2025

Utilization of dexrazoxane in patients treated with doxorubicin: a retrospective, propensity matched analysis of cardiac function and toxicity

in Pharmacology of Anti-Cancer Drugs

Zachary M. Neiman
Carlo S. Legasto
Alan K. Chin
Tiffany Guan
Brian C. Schulte

Frontiers in Oncology

doi 10.3389/fonc.2025.1621409

834 views